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Abstract

Purpose: To determine whether radical prostatectomy (RP) or intensity
modulated radiation therapy (IMRT) to ≥72 Gy, plus hormonal therapy if
indicated, results in improved biochemical disease free survival (BDFS) in
localized prostate adenocarcinoma.

Methods and Materials: Between 1997-2005, a consecutive sample of 556
patients who underwent RP (n=204) or IMRT (n=352) at two referral centers was
analyzed. Patients were stratified into prognostic groups based on clinical stage,
Gleason score, and pretreatment prostate specific antigen (PSA) level as
outlined by schemes designed by Memorial Sloan Kettering (MSK) and the
National Comprehensive Cancer Network (NCCN). The outcome used in this
study was BDFS. Median follow up in the RP and IMRT cohorts was 46 months
and 40 months, respectively.

Results: IMRT patients had more advanced and aggressive disease at baseline
(p<.001). No difference was found in five-year BDFS rates between RP and
IMRT in the favorable prognosis (92.8% vs. 85.3%, p=.20) or the MSK
intermediate prognosis (86.7% vs. 82.2%, p=.46) subsets. A difference favoring
IMRT was seen in the NCCN intermediate prognosis (70.7% vs. 83.3%, p=.03),
MSK poor prognosis (38.4% vs. 62.2%, p<.001), and NCCN poor prognosis
(37.0% vs. 56.8%, p=.005) subsets. Within the entire cohort, after adjustment for
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confounding variables, Gleason score (p<.001) and clinical stage (p<.001)
predicted BDFS, but treatment modality (p=.06) did not. Within the MSK poor
prognosis subset, treatment modality (p=.006) was predictive of BDFS, favoring
IMRT.

Conclusion: Biochemical disease free survival is similar between RP and IMRT
for patients with a good prognosis. Patients with a poor prognosis, and some with
an intermediate prognosis, may benefit from IMRT to ≥72 Gy plus hormonal
therapy.
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1
Introduction
Prostate cancer is second only to nonmelanoma skin cancer as the most
common form of cancer in American men and it is estimated that 218,890
American men were diagnosed with prostate cancer in 2007.1 Prostate cancer
represents the second leading cause of cancer-related death in American men,
accounting for an estimated 27,050 deaths in 2007.1 Over the past two decades,
prostate cancer has become more commonly diagnosed at earlier stages of
disease, likely due to the increased availability of prostate specific antigen (PSA)
assays.2 Currently, over 80% of newly diagnosed prostate cancer patients have
clinically localized disease,3 and as a result the number of men receiving local
treatment with curative intent has increased.4
Treatment of patients diagnosed with localized prostate cancer (T1T3N0M0)5 centers around one of four options: observation, radical prostatectomy
(RP), external beam radiation therapy, or brachytherapy. Observation alone has
been shown in a prospective, randomized, controlled study to yield inferior
outcomes when compared to surgery.6, 7 This study randomized 695 men with
stage T1-T2 prostate cancer (i.e., cancer confined to the prostate) to either RP or
observation. With a median follow up of 8.2 years, RP yielded a statistically
significant improvement in overall survival and disease-specific survival when
compared to observation alone.6, 7 As a result, observation is generally only
appropriate for older patients with significant comorbidities and limited life
expectancy, as these patients may not be candidates for more aggressive
treatment, such as surgery or radiation. However, the debate regarding

2
observation versus treatment in patients with very early, localized, nonaggressive (i.e., low Gleason score and PSA levels) cancer continues.8, 9
Only patients with early, low-grade cancers are candidates for
brachytherapy alone, as several series have reported poorer outcomes in
patients with a clinical stage greater than T2a (i.e., the tumor can be palpated in
less than half of one of the prostate gland's two lobes), a Gleason score of
greater than 6, or a pretreatment PSA of greater than 10 ng/mL.10, 11 In a
retrospective study, which examined 1872 men treated with either RP,
brachytherapy, or external beam radiation therapy, brachytherapy was found to
yield statistically worse rates of biochemical control in patients with a clinical
stage of T2b or greater, a Gleason score of greater than 6, or a pretreatment
PSA of greater than 10 ng/mL when compared to the other two treatment
modalities.11 Other retrospective studies12 and systematic reviews13 have found
similar results.
Unlike brachytherapy or observation, RP and external beam radiation
therapy (with or without hormonal therapy) are appropriate options for almost all
patients with localized prostate cancer, regardless of clinical stage, Gleason
score, or pretreatment PSA.10, 14 To date, only one prospective trial has been
performed comparing RP and external beam radiation therapy in American
men.15 The trial was published in 1982 and included 97 patients, all with T1-T2
disease (i.e., disease confined to the prostate). Forty one patients were
randomized to RP and 56 patients were randomized to external beam radiation
therapy. This trial found that RP yielded higher progression-free survival than
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external beam radiation therapy at five years post-therapy (p=.04). However, this
study is now outdated and was limited by numerous methodological flaws.16-18
Some physicians who enrolled patients in the trial did not use the specified
randomization scheme, raising concern for physician selection bias. The study
permitted cross-over between treatment arms and the analysis was not done on
an intent-to-treat basis; rather, the analysis was based on the actual treatment
given, which generally is not standard practice when designing randomized trials.
Pathologic stage C patients (i.e., those with the poorest prognosis) were
excluded from the surgical arm but allowed in the radiation arm and a worse than
previously reported outcome was seen among external beam radiation therapy
patients. Additionally, the authors did not provide data as to the pretreatment
characteristics of each cohort (e.g. Gleason score, acid phosphatase level, age,
race etc…), and no multivariable analysis was performed. A multivariable
analysis would be necessary to account for the impact of clear differences in the
respective cohorts, such as the pathologic stage of patients included in the study.
As a result of these limitations, it is difficult to form any meaningful conclusions
regarding RP versus external beam radiation therapy in the treatment of localized
prostate cancer based on this single trial.16-18
A number of retrospective reviews have attempted to compare RP and
external beam radiation therapy.11, 19-25 Of the contemporary reviews (i.e., those
published in the past twelve years, in which all patients received PSA follow up),
all used biochemical disease free survival (BDFS) as the primary outcome
measure. Nearly all studies stratified patients based on the proven prognostic
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factors of pretreatment PSA, Gleason score, and clinical stage. Patients treated
with surgery almost always underwent a radical retropubic prostatectomy, often
times with a lymph node dissection, while patients treated with external beam
radiation therapy frequently were treated via a conformal technique. Radiation
doses ranged from a median of 66 Gy to a median of 70.2 Gy, with the exception
of the review by Keyser et al.19 in which the median dose of radiation was 74 Gy
(range 70 Gy to 83 Gy).
Most prior retrospective reviews found no difference in outcome between
RP and external beam radiation therapy in all prognostic groups,11, 19-21, 24 with
the following exceptions. A review by D’Amico et al. found improved BDFS in
patients who underwent a radical prostatectomy, as opposed to external beam
radiation therapy, if they had a favorable prognosis (defined as patients with a
pretreatment PSA of 10 ng/mL or less, a Gleason score of 6 or less, and a
clinical stage of T2a or less) or an intermediate prognosis (defined as patients
with a pretreatment PSA of greater than 10 ng/mL but less than 20 ng/mL, a
Gleason score of 7, or a clinical stage of T2b), provided that these patients
carried a low tumor volume (defined as <34% of positive biopsies). However, in
patients with an intermediate prognosis, the difference in outcome was no longer
significant at 10 years post therapy.
In a retrospective review by Kupelian et al., initial analysis revealed no
difference in BDFS in any prognostic group. However, on subgroup analysis of
patients with a poor prognosis (defined as a pretreatment PSA of greater than 10
ng/mL, a Gleason score of 7 or greater, or a clinical stage of T2b or greater),
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patients who received external beam radiation therapy to a dose of at least 72 Gy
had significantly better BDFS when compared to patients who underwent RP
(p=.004), while patients treated with external beam radiation therapy to a dose
less than 72 Gy had significantly poorer BDFS than patients who underwent RP
(p<.001).22 A subsequent retrospective study by Kupelian et al. also found that
external beam radiation therapy to a dose of less than 72 Gy yielded inferior
biochemical disease free survival when compared to RP. This result was seen in
the whole cohort and among each prognostic group.23
Collectively, these retrospective studies seem to indicate that RP and
external beam radiation therapy generally yield similar outcomes in patients with
prostate cancer, but also that the dose of radiation used to treat patients may
impact the results of the trial.
Since the last study comparing RP and external beam radiation therapy
was carried out, novel strategies in the management of localized prostate cancer
have been adopted by the oncology community. The standard of care for
external beam radiation therapy now centers on a relatively new approach,
intensity modulated radiation therapy (IMRT).26-29 IMRT, which became widely
available 5-10 years ago, offers the ability to modulate individual beams of
radiation so that the intensity of photons within a particular beam can be varied.
This facilitates the ability to deliver high doses of radiation to the tumor, while
administering relatively low doses of radiation to surrounding tissues, such as the
bowel and bladder in cases of prostate cancer.30 High doses of radiation (those
exceeding 72 Gy) have been decidedly shown to improve outcomes in patients
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with prostate cancer31-33 (as suggested by the retrospective studies comparing
RP and external beam radiation therapy), and IMRT is the preferred radiotherapy
technique because its lower side effect profile, compared to other forms of
external beam radiation therapy, allows higher doses of radiation to safely be
used in the treatment of prostate cancer.23, 34-36 With non-IMRT based
approaches, it may not be feasible to safely deliver high doses of radiation to the
prostate without exceeding the tolerance of the surrounding bowel and bladder,
thereby resulting in serious acute and late radiation toxicity.37, 38 To date, no
study has compared IMRT to RP in the treatment of prostate cancer. In addition,
no previous review has only included patients treated to 72 Gy or higher, now
considered the standard of care.39
Since the publication of the last retrospective review comparing RP to
external beam radiation therapy, hormonal therapy has become a mainstay
adjunctive treatment for patients with an intermediate or poor prognosis when
given in conjunction with radiation.40-44 In Radiation Therapy Oncology Group
Trial 8610, patients were randomized to external beam radiation with or without
four months of goserelin (a gonadotropin releasing hormone agonist) plus
flutamide (an androgen receptor antagonist) in the neoadjuvant/concurrent
setting. At a median follow up of 12.5 years, the cohort randomized to hormonal
therapy displayed decreased disease-specific mortality, distant metastases, and
biochemical failures.45 Another prospective trial randomized locally advanced
prostate cancer patients to either external beam radiation alone or radiation plus
three years of concurrent/adjuvant goserelin plus one month of cyproterone (an
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androgen receptor antagonist). At a median follow up of 66 months, hormonal
therapy significantly improved disease free survival and overall survival.46, 47
Other prospective studies have found similar results.48 As a result, hormonal
therapy is generally indicated in patients treated with external beam radiation
therapy who have an intermediate or poor prognosis (i.e., patients with a
pretreatment PSA of greater than 10 ng/mL, a Gleason score of greater than 6,
or a clinical stage of greater than T2a); hormonal therapy is not indicated in
patients who undergo surgery because no benefit has been seen in surgical
patients who undergo adjuvant hormonal therapy.40, 48, 49
In all previous reviews, patients receiving hormonal therapy were excluded
from the analysis19-21, 24, 25 or only a small percentage of patients in the review
received hormonal therapy. Specifically, in a review published by Kupelian et al.,
17% of RP patients and 23% of external beam radiation therapy patients
received hormonal therapy. In another review by Kupelian et al. 17% of RP
patients and 5-39% of external beam radiation therapy patients (depending on
prognostic group) received hormonal therapy.22, 23 In all other retrospective
studies cited in this thesis, no patients were treated with hormonal therapy.
Another limitation of prior retrospective studies comparing RP and external
beam radiation therapy pertains to the varying definitions of "post-treatment
biochemical failure" used in each review. Although all definitions of posttreatment biochemical failure are based on PSA levels,50 each definition carries a
different sensitivity and specificity for true clinical failure.51-53 Therefore, it is
difficult to interpret the results of previous retrospective studies. For example, of
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the aforementioned retrospective reviews comparing RP to external beam
radiation therapy, four definitions of post-RP biochemical failure were used
including “two PSA levels of greater than 0.2 ng/mL”,22-24 “two detectable PSA
levels”,20 “a single PSA of at least 0.2 ng/mL”,19, 21 and “three consecutive PSA
rises”.11, 25 Post external beam radiation therapy definitions have varied as well
and have included “three consecutive rises in PSA level”,11, 21-25 “two consecutive
rises in PSA level”,20 and “PSA nadir plus one ng/mL”.19 To combat this problem,
in 2006 the American Society for Therapeutic Radiology and Oncology (ASTRO)
published guidelines recommending that the definition of post-external beam
radiation therapy biochemical failure be established as absolute PSA nadir + 2
ng/mL.54 No retrospective study has used this definition of post external beam
radiation therapy biochemical failure. Another benefit of the updated definition of
post-external beam radiation therapy biochemical failure is that it can be applied
if a patient receives external beam radiation therapy and hormonal therapy,
which is not the case with previous definitions because data used to derive these
definitions was obtained from patients who were not treated with hormonal
therapy.54 For patients treated with RP, the American Urological Association
(AUA) guidelines, published in 2007, define post-treatment failure as a single
PSA of 0.2 ng/mL, with a second confirmatory PSA exceeding 0.2 ng/mL.55 No
review has used this definition of post-RP failure, although many have used
similar definitions.
The primary goal of this study was to retrospectively compare radical
prostatectomy to dose-adequate intensity modulated radiation therapy plus
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hormonal therapy, if indicated, in patients with localized prostate cancer, using
modern definitions of biochemical disease free survival as the outcome measure.
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Hypothesis and Specific Aims

The primary goal of this study was to retrospectively compare radical
prostatectomy to dose-adequate intensity modulated radiation therapy plus
hormonal therapy, if indicated, in patients with localized prostate cancer, using
modern definitions of biochemical disease free survival as the outcome measure.

11
Methods and Materials

Study Design and Patient Populations

We conducted a retrospective observational cohort study of a consecutive
sample of 708 patients treated for localized prostate adenocarcinoma between
1997-2005; 495 patients received radiation therapy and 213 underwent surgery.
Patients receiving post-operative radiation were excluded from the study.
Patients treated with radiation therapy received treatment at either Yale New
Haven Hospital (New Haven, CT, 373 patients) or Lawrence & Memorial Hospital
(New London, CT, 122 patients). All 213 patients treated surgically underwent a
radical retropubic prostatectomy at Yale New Haven Hospital. Patients were
excluded from the IMRT group if they lacked three post-treatment PSA levels
(n=97), were treated to doses under 72 Gy (n=45), or lacked adequate
pretreatment staging (n=1), leaving 352 patients in the IMRT group. Patients
were excluded if they lacked three post-treatment PSA values because of the
inability to apply the “nadir + 2” definition of failure in such cases. Patients were
excluded from the RP cohort if they lacked an accessible follow up PSA (n=7) or
underwent a salvage prostatectomy after failed radiation therapy (n=2), leaving
204 patients in the RP cohort.

Staging
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Before receiving therapy, all patients underwent a clinical history and
physical including digital rectal examination, PSA level, and ultrasound guided
transrectal prostate biopsy with Gleason score histological grading. Other staging
modalities such as computed tomography of the pelvis, magnetic resonance
imaging of the prostate or pelvis, positron emission tomography, or bone
scanning were performed at the discretion of the attending physician. No patient
was found to have metastatic disease after staging evaluation. Staging was
performed in accordance with the 1992 AJCC staging system.5 A summary of the
AJCC clinical staging of prostate cancer, as presented by the National Cancer
Institute, is presented below:
TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Clinically unapparent tumor not palpable nor visible by imaging
T1a: Tumor incidental histological finding in 5% or less of tissue resected
T1b: Tumor incidental histological finding in more than 5% of tissue
resected
T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA)
T2: Tumor confined within prostate
T2a: Tumor involves 50% or less of one lobe
T2b: Tumor involves more than 50% of one lobe but not both lobes
T2c: Tumor involves both lobes
T3: Tumor extends through the prostate capsule
T3a: Extracapsular extension (unilateral or bilateral)
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T3b: Tumor invades seminal vesicle(s)
T4: Tumor is fixed or invades adjacent structures other than seminal vesicles:
bladder neck, external sphincter, rectum, levator muscles, and/or pelvic wall

Prognostic Groups

Patients were stratified into prognostic groups based on the prognostic
parameters of clinical stage, Gleason score, and PSA level. Each of these
prognostic factors independently predicts outcome in patients with prostate
cancer.56-60 Two prognostic group schemes were chosen; these appear to be the
schemes most commonly used by clinicians in practice.3, 19, 20, 23, 61
In the Memorial Sloan Kettering (MSK) scheme,62, 63 the favorable
prognosis group consisted of patients with a clinical stage ≤T2a, a Gleason score
≤6, and a pretreatment PSA ≤10 ng/mL. Patients in the intermediate and poor
prognosis groups presented with one and two or more unfavorable prognostic
parameters (clinical stage >T2a, Gleason score >6, or PSA>10), respectively.
The data were also analyzed using the National Comprehensive Cancer
Network (NCCN) scheme,64 in which the favorable prognosis group also
consisted of patients with a clinical stage ≤T2a, a Gleason score ≤6, and a
pretreatment PSA ≤10. The intermediate prognosis group contained patients with
a clinical stage of T2b-T2c, a Gleason score of 7, or a pretreatment PSA
between 10-20 ng/mL. The poor prognosis group consisted of patients with a
clinical stage of ≥T3a, a Gleason score ≥8, or a pretreatment PSA of >20 ng/mL.
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Treatment

Patients who opted for surgery underwent radical retropubic
prostatectomy with bilateral lymph node dissection. Nearly all of the surgeries
were performed by the same surgeon, an experienced urologic oncologist
practicing at Yale New Haven Hospital, a tertiary care medical center.
The vast majority (96.3%) of patients opting for radiation received exactly
75.6 Gy in 1.8 Gy fractions (others treated to 72.0 - 77.4 Gy). Radiation was
delivered with an isocentric, five-field technique, using 18 MV or 10 MV photons.
IMRT was utilized, at least in part, to treat all patients undergoing radiation; 112
patients (31.8%) received 3D conformal radiation therapy (3DCRT) and IMRT,
203 patients (57.7%) received IMRT alone, and 37 patients (10.5%) received
four-field whole pelvic radiation with an IMRT guided boost to the prostate.
Patients treated with 3DCRT and IMRT were treated to 66.6 Gy with
3DCRT using a planning target volume (PTV) defined as a 1.5 cm margin around
the tumor volume (TV) in three dimensions, followed by a 9.0 Gy IMRT based
cone down using a margin of 1.0 cm around the tumor volume, except for the
rectal-prostate interface, where a 0.6 cm margin was used. Patients treated with
IMRT alone were treated to 66.6 Gy with IMRT using a PTV defined as a 1.2 cm
margin around the tumor volume in three dimensions, followed by a 9.0 Gy IMRT
based cone down using a margin of 1.0 cm around the tumor volume, except for
the rectal-prostate interface, where a 0.6 cm margin was used.
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Whole pelvic radiation patients received 45.0 Gy to the whole pelvis with a
30.6 Gy IMRT based cone down as described above. To deliver whole pelvic
radiation, a four-field technique utilizing bony landmarks was employed. A fourfield technique was chosen, as opposed to an IMRT-based plan, because of data
suggesting that IMRT does not improve lymph node coverage in advanced
prostate cancer.65 Whole pelvic radiation was designed to cover the obturator,
internal iliac, external iliac, pre-sacral, and peri-rectal nodes, as these are the
most common lymph node groups involved in prostate cancer.65 The superior,
lateral, and inferior borders of the whole pelvic field were at L5/S1, 2.0 cm lateral
to the pelvic brim, and 0.5 cm inferior to the obturator foramen, respectively.66
The inferior border employed in our study has been shown to adequately cover
the apex of the prostate.67 The decision to administer whole pelvic radiation was
made at the discretion of the attending physician. Commonly, patients with at
least a 15% likelihood of lymph node involvement, as predicted by the Roach
formula,68 were considered for whole pelvic radiation therapy. The Roach formula
accounts for Gleason score and pretreatment PSA in ascertaining the likelihood
of lymph node involvement and is presented here:

% likelihood of lymph node involvement = 2/3*(PSA) + 10*(Gleason score-6)

Within the IMRT group, 30 patients in the MSK favorable prognosis group
(37.5%), 138 patients in the intermediate prognosis group (89.0%), and 114
patients in the poor prognosis group patients (97.4%) received hormonal therapy,
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consisting of a gonadotropin releasing hormone agonist in 56.5% of patients, an
androgen receptor antagonist in 3.6% of patients, and combined modality
therapy in 39.9% of patients. Patients in the intermediate and poor prognosis
groups generally received 6 months and 12-24 months of hormonal therapy,
respectively. After treatment, patients were followed up routinely with PSA testing
and digital rectal exams. Follow-up visits typically occurred one month after
completion of treatment, every 3-6 months for the following two years, and every
6-12 months thereafter. The median follow up was 46 months in the RP cohort
and 40 months in the IMRT cohort.

Verification of Data

We employed methods recommended in the literature to ensure the
validity and reliability of data collected.69 Upon completion of data collection, a
second reviewer blindly reabstracted a random sample of 30 charts, representing
5.4% of the 556 charts reviewed. The overall mean percentage agreement
between the two reviewers was 100% across all variables. To measure interrater
agreement for nominal variables, a kappa statistic was calculated and found to
be 1.0.

Statistical Methods
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Baseline patient characteristics were compared using the chi-square test
for categorical variables and the unpaired t-test for continuous variables. If a
categorical variable contained less than five patients, Fisher’s exact test was
used instead.
Biochemical failure was defined in IMRT patients as absolute PSA nadir +
2 ng/mL. The date of failure was defined as the date at which the post-treatment
PSA exceeded the nadir + 2 ng/mL. Post-RP biochemical failure was defined as
a single PSA of at least 0.2 ng/mL, with a second confirmatory PSA of greater
than 0.2 ng/mL. The date of failure was defined as the date at which the PSA
reached 0.2 ng/mL. Data was censored at the date of last PSA level. The data
were not analyzed with alternative definitions of biochemical failure or with an
alternative prognostic group scheme.
Biochemical disease free survival was calculated using the Kaplan-Meier
method, graphically displayed, and compared with the log-rank test. Biochemical
disease free survival rates at individual post-treatment times were compared by
calculating the quotient of the difference in survival (between RP and IMRT
cohorts at a given time point) squared and the weighted variance of the survival
functions, and subsequently comparing this quotient to the chi-square distribution
using one degree of freedom.70
With the use of proportional hazards analysis, hazard ratios and 95%
confidence intervals were generated for the unadjusted association between
baseline characteristics and biochemical failure. To examine the impact of
confounding factors, a Cox proportional hazards multivariate analysis was
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performed using the following variables: age, race, prior transurethral resection of
the prostate (TURP), clinical stage, Gleason score, pretreatment PSA, treatment
modality (RP vs. IMRT), type of radiation therapy employed, hospital of
treatment, and hormonal therapy. To remain in the model, variables were
required to have a p value of <.20.
All reported p values are two-sided. Statistical analysis was performed
using SAS version 9.1. This study was approved by the Institutional Review
Board of Yale School of Medicine. The study was carried out in a manner
consistent with the Helsinki Declaration of 1975, as revised in the year 2000.
Written consent was not obtained from participants (i.e., a waiver was granted)
because this was a retrospective review of existing patient data.
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Results

Patient Characteristics

Pretreatment and treatment-related patient characteristics are
summarized by treatment modality in Table 1.

Table 1. Pretreatment and Treatment-Related Patient Characteristics
Pretreatment Parameter

RP patients

IMRT patients

All patients

N

N

N

%

%

P

%

Age

<.001
≤65

179

88

100

28

279

50

>65

25

12

252

72

277

50

Race

0.27*
White

174

85

284

81

458

82

American

29

14

62

18

91

16

Asian

0

0

4

2

4

1

Hispanic

1

0.5

2

1

3

1

African

Prior TURP

<.001
Yes

2

1

23

7

25

4

No

202

99

329

93

531

96

Clinical
Stage

0.01†
T1-T2a

152

75

294

84

446

80

21
T2b-T2c

51

25

31

9

82

15

T3a

1

0.5

26

7

27

5

T3b

0

0

1

0.3

1

0.2

Gleason
Score (total)

<.001
≤6

144

71

126

36

270

49

7

49

24

145

41

194

35

≥8

11

5

81

23

92

17

Pretreatment
PSA

<.001
≤4

29

14

28

8

57

10

>4 to ≤10

138

68

191

54

329

51

>10 to ≤20

29

14

89

25

118

29

>20

8

4

44

13

52

9

MSK
Prognosis
Group

<.001
Favorable

103

50

80

23

183

33

Intermediate

59

29

155

44

214

38

Poor

42

21

117

33

159

29

NCCN
Prognosis
Group

<.001
Favorable

103

50

80

23

183

33

Intermediate

84

41

150

43

234

42

Poor

17

8

122

35

139

25

Method of
Radiation

n/a

22
3DCRT+IMRT

n/a

112

32

n/a

IMRT alone

n/a

201

57

n/a

n/a

39

11

n/a

Whole Pelvic
IMRT
Treatment
Site

<.001
Lawrence &
Memorial
Hospital

0

0

71

20

71

13

204

100

281

80

485

87

Yale New
Haven
Hospital
Hormonal
Therapy

<.001
Yes

6

3

282

80

288

52

No

198

97

70

20

268

48

*p value represents Chi-Square between White patients and African
American patients
†p value represents Chi-Square for clinical stage ≤ T2a vs. >T2a

Abbreviations: RP = Radical Prostatectomy; IMRT = Intensity Modulated
Radiation Therapy; 3DCRT = 3 Dimensional Conformal Radiation
Therapy; PSA = Prostate Specific Antigen; MSK = Memorial Sloan
Kettering; NCCN = National Comprehensive Cancer Network; TURP =
Transurethral Resection of the Prostate
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Patients in the IMRT group were older, and had higher Gleason scores
and pretreatment PSA levels, than patients in the RP group (p<.001 in all cases).
Although more RP patients had a clinical stage ≥T2b (p=.01), more IMRT
patients had T3 disease (p<.001). Patients in the IMRT cohort had more
advanced disease, as judged by both the MSK and NCCN prognostication
schemes (p<.001). There was no significant difference in race between RP and
IMRT cohorts.

Treatment Outcome

Three-year and five-year biochemical disease free survival rates for the
combined and individual prognostic groups are displayed in Table 2.

Table 2. Biochemical Disease Free Survival Rates in RP and IMRT Patients
Cohort

3 yr BDFS

95% CI

Whole cohort

p

5 yr BDFS

95% CI

0.004

0.37

RP

83.5

76.9-88.3

78.4

70.5-84.3

IMRT

91.7

87.7-94.5

74.8

66.2-81.5

MSK favorable

0.45

0.20

RP

95.1

87.4-98.1

92.8

83.0-97.1

IMRT

97.3

89.7-99.3

85.3

68.6-93.5

MSK inter

p

0.13

0.46

RP

86.7

72.4-93.9

86.7

72.4-93.9

IMRT

94.0

88.2-97.0

82.2

69.3-90.1
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MSK poor

<.001

<.001

RP

53.8

36.8-68.0

38.4

21.8-54.8

IMRT

85.8

76.8-91.6

62.2

47.0-74.3

NCCN
favorable*

0.45

0.20

RP

95.1

87.4-98.1

92.8

83.0-97.1

IMRT

97.3

89.7-99.3

85.3

68.6-93.5

NCCN inter

0.002

0.03

RP

77.5

65.7-85.6

70.7

57.2-80.6

IMRT

91.7

85.0-95.5

83.3

72.0-90.4

NCCN poor

<.001

0.005

RP

49.3

23.0-71.2

37.0

11.6-63.1

IMRT

88.0

79.3-93.3

56.8

39.4-71.0

*The favorable prognosis group in the MSK and NCCN prognostication schemes
consists of the same patients.

Abbreviations: RP = Radical Prostatectomy; IMRT = Intensity Modulated Radiation
Therapy; MSK = Memorial Sloan Kettering; NCCN = National Comprehensive Cancer
Network; CI = Confidence Interval

No significant difference in biochemical disease free survival was
observed between RP and IMRT at any time point within the MSK/NCCN
favorable and the MSK intermediate prognosis subsets. Differences in
biochemical disease free survival favoring the IMRT group were seen in the MSK
poor prognosis subset at three (p<.001) and five (p<.001) years post-treatment,
the NCCN poor prognosis subset at three (p<.001) and five (p=.005) years post-
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treatment, and the NCCN intermediate prognosis subset at three (p=.002) and
five (p=.03) years post-treatment.
Kaplan-Meier curves comparing biochemical disease free survival in RP
and IMRT patients are displayed in Figure 1:

Figure 1: Biochemical Disease Free Survival Rates for Whole Cohort and
Individual Prognostic Groups
Whole Cohort (Figure 1a)

MSK Intermediate Prognostic Group
(1c)

MSK/NCCN Favorable Prognostic
Group (1b)

MSK Poor Prognostic Group (1d)

26
NCCN Intermediate Prognostic
Group (1e)

NCCN Poor Prognostic Group (1f)

Legend: Biochemical disease free survival in RP and IMRT patients in the whole
cohort (a), MSK/NCCN favorable prognosis group (b), MSK intermediate
prognosis group (c), MSK poor prognosis group (d), NCCN intermediate
prognosis group (e), and NCCN poor prognosis group (f).

No significant difference in survival curves was seen in the overall study
population, MSK/NCCN favorable prognosis subset, or MSK intermediate
prognosis subset. Patients in the MSK poor prognosis subset (p<.001), NCCN
intermediate prognosis subset (p=.03), and NCCN poor prognosis subset
(p=.004) displayed higher biochemical disease free survival when treated with
IMRT.
An unadjusted analysis and Cox proportional hazards multivariable
(adjusted) analysis of the entire study population are shown in Table 3.
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Table 3. Unadjusted and Adjusted Analysis of Patient Characteristics
and Biochemical Failure for Entire Cohort
Unadjusted

Adjusted

Clinical

Unadjusted

Hazard

Adjusted

Hazard

Parameter†

p value

Ratio

95% CI

p value

Ratio

95% CI

Age

0.68

1.00

0.97-1.02

Race*

0.51

1.19

0.70-2.03

Prior TURP

0.40

1.83

0.44-7.52

<.001

3.60

2.34-5.53

<.001

2.42

1.52-3.85

<.001

2.19

1.66-2.90

<.001

2.02

1.47-2.79

0.009

1.42

1.09-1.83

0.19

1.20

0.92-1.56

0.74

0.93

0.59-1.45

0.06

0.62

0.38-1.03

0.08

0.55

0.28-1.06

0.43

1.42

0.60-3.35

0.02

1.64

1.07-2.52

Clinical
Stage
Gleason
Score (total)
Pretreatment
PSA
Treatment
Modality
Method of
Radiation††
Treatment
Site†††
Hormonal
Therapy

*only Whites and African Americans were compared in
this analysis
† Coding of clinical parameters: Age (continuous, per year), Race (reference = white),
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Prior TURP (reference = no TURP), Clinical Stage (T1-T2a versus T2b-T2c versus
T3a-T3b, reference = T1-T2a), Gleason Score (<7 versus 7 versus >7, reference =
<7), Pretreatment PSA (continuous, per ng/mL increment), Treatment Modality
(reference = RP), Method of Radiation (reference = 3DCRT + IMRT), Treatment Site
(reference = Lawrence & Memorial Hospital), Hormonal Therapy (reference = no
hormonal therapy)
††only 3DCRT+IMRT and IMRT alone were compared in this analysis
†††only includes patients treated with radiation
Abbreviations: IMRT = Intensity Modulated Radiation Therapy; 3DCRT = 3 Dimensional
Conformal Radiation Therapy; PSA = Prostate Specific Antigen; TURP = Transurethral
Resection of the Prostate; CI = Confidence Interval

In unadjusted analysis, clinical stage (Hazard Ratio 3.60, 95% CI 2.345.53, p<.001), Gleason score (Hazard Ratio 2.19, 95% CI 1.66-2.90, p<.001),
and pretreatment PSA (Hazard Ratio 1.42, 95% CI 1.09-1.83, p= .009) predicted
BDFS, but treatment modality did not (p=.74). After adjustment, clinical stage
(Hazard Ratio 2.42, 95% CI 1.52-3.85, p<.001) and Gleason score (Hazard Ratio
2.02, 95% CI 1.46-2.79, p<.001) were predictive of BDFS, but the impact of
treatment modality (Hazard Ratio 0.62, 95% CI 0.38-1.03, p=.06, favoring IMRT)
and pretreatment PSA (Hazard Ratio 1.20, 95% CI 0.92-1.56, p=.19) did not
achieve statistical significance. Additionally, race (p=.22) and age (p=.58) did not
affect biochemical disease free survival on multivariable analysis.
An unadjusted and adjusted analysis were performed on the MSK poor
prognosis group as well (Table 4).
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Table 4. Unadjusted and Adjusted Analysis of Patient Characteristics
and Biochemical Failure for MSK Poor Prognosis Subset
Unadjusted
Clinical

Unadjusted

Hazard

Parameter†

p value

Ratio

Age

0.003

Race*
Prior TURP

Adjusted
Adjusted

Hazard

95% CI

p value

Ratio

95% CI

0.43

0.24-0.76

0.08

0.96

0.92-1.00

0.81

1.08

0.56-2.08

0.79

1.21

0.29-5.15

0.02

2.02

1.11-3.68

0.04

1.69

1.03-2.80

0.001

2.20

1.36-3.57

0.41

0.87

0.62-1.22

<.001

0.36

0.20-0.63

0.006

0.39

0.20-0.77

0.12

0.45

0.16-1.22

Clinical
Stage
Gleason
Score (total)
Pretreatment
PSA
Treatment
Modality
Method of
Radiation††
Treatment
Site†††

0.410.28

3.02

22.40

0.08

0.60

0.34-1.06

Hormonal
Therapy

*only Whites and African Americans were compared in this analysis

† Coding of clinical parameters: Age (continuous, per year), Race (reference = white), Prior
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TURP (reference = no TURP), Clinical Stage (T1-T2a versus T2b-T2c versus T3a-T3b,
reference = T1-T2a), Gleason Score (<7 versus 7 versus >7, reference = <7), Pretreatment
PSA (continuous, per ng/mL increment), Treatment Modality (reference = RP), Method of
Radiation (reference = 3DCRT + IMRT), Treatment Site (reference = Lawrence & Memorial
Hospital), Hormonal Therapy (reference = no hormonal therapy)
††only 3DCRT+IMRT and IMRT alone were compared in this analysis
†††only includes patients treated with radiation

Abbreviations: IMRT = Intensity Modulated Radiation Therapy; 3DCRT = 3 Dimensional
Conformal Radiation Therapy; PSA = Prostate Specific Antigen; TURP = Transurethral
Resection of the Prostate; CI = Confidence Interval

In unadjusted analysis, age (Hazard Ratio 0.43, 95% CI 0.24-0.76,
p=.003), clinical stage (Hazard Ratio 2.02, 95% CI 1.11-3.68, p=.02), Gleason
score (Hazard Ratio 1.69, 95% CI 1.03-2.80, p=.04), and treatment modality
(Hazard Ratio 0.36, 95% CI 0.20-0.63, p<.001) were significant predictors of
biochemical disease free survival. In multivariable analysis, only Gleason score
(Hazard Ratio 2.20, 95% CI 1.36-3.57, p=.001) and treatment modality (Hazard
Ratio 0.39, 95% CI 0.20-0.77, p= .006) predicted biochemical failure. The p value
for age (p=.08) did not reach statistical significance.
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Discussion

We conducted a retrospective cohort study to investigate whether RP or
IMRT, plus hormonal therapy if indicated, is associated with improved
biochemical disease free survival compared to the alternative modality. Our
results suggest that there is no difference in outcome for patients with a favorable
prognosis, but patients with a poor prognosis and some patients with an
intermediate prognosis (those in the NCCN intermediate prognosis group) may
have improved outcomes when treated with IMRT and hormonal therapy.
Patients in the IMRT cohort had more advanced and aggressive disease
than their RP counterparts, as indicated by the significantly higher Gleason
scores, pretreatment PSA values, and amount of extracapsular (T3) disease at
presentation. This explains the change in unadjusted (p=.74) versus adjusted
(p=.06) p values associating treatment modality to outcome (Table 3) and should
be considered in the interpretation of our results.
Interestingly, the rates of BDFS seen in the RP cohort are similar to rates
seen in other studies20, 25 and are marginally better than those predicted by the
Kattan nomogram for post-RP patients;71 in the MSK favorable, intermediate, and
poor prognostic groups, the Kattan nomogram-predicted versus our observed
five-year biochemical disease free survival rates (respectively) are 90.8% versus
95.1%, 81.8% versus 86.7%, and 43.8% versus 53.8%.
Our rates of BDFS for patients treated with IMRT are similar to those
reported in other series,20, 25, 61 including the Kattan nomogram-predicted rates
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for post external beam radiation patients,72 with the exception of patients in the
poor prognostic group subsets of the IMRT cohort. These patients may have
better outcomes than those in some previously reported series. This finding may
be attributable to our study including patients treated to at least 72 Gy, which
other studies suggest yields better outcomes than doses less than 72 Gy.
Kupelian et al. found that, on unplanned subgroup analysis, patients with an
unfavorable prognosis (clinical stage ≥T2b, Gleason Score ≥7, or pretreatment
PSA >10) have significantly higher biochemical disease free survival rates when
treated with external beam radiation therapy to ≥72 Gy as opposed to RP, but a
significantly worse biochemical disease free survival when treated with external
beam radiation therapy to <72 Gy compared to RP.22 Additional support for
treating patients to doses ≥72 Gy comes from a randomized trial comparing
external beam radiation therapy of 78 Gy to external beam radiation therapy of
70 Gy, which showed improved five-year biochemical disease free survival in the
78 Gy arm (78% vs. 68%, p=.03). This result was even more striking when
patients with a pretreatment PSA of >10 ng/mL were examined (72% vs. 43%,
p=.01), suggesting that patients with an unfavorable prognosis derive the most
benefit from dose escalation.39 Another prospective trial randomized patients to
external beam radiation therapy to a dose of either 68 Gy or 78 Gy. Patients in
the 78 Gy arm showed significantly higher disease free survival rates than
patients in the 68 Gy arm.32 A similar result was seen by Zelefsky et al., who
noted improved BDFS in patients treated to 81.0 Gy, as compared to those
treated to 64.8 Gy.33 Dose escalation could explain why our study found an
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improvement in BDFS in the poor prognosis subsets of the IMRT cohort, relative
to the RP cohort, as no other previous study utilized radiation doses as high as
those used in our study.
The higher biochemical disease free survival seen in IMRT patients with a
poor prognosis could also be attributable to the hormonal therapy given in
conjunction with radiation, as hormonal therapy is theorized to eliminate residual
local disease in patients treated with external beam radiation therapy. Hormonal
therapy has been shown in prospective trials to improve overall survival and
disease-specific survival in poor prognosis patients, and some intermediate
prognosis patients, treated with external beam radiation therapy, as illustrated by
RTOG 8610 and a prospective study published by Bolla et al (discussed in the
introduction).40, 41, 45, 47 We unfortunately do not have the capability to determine
whether the improvement in BDFS seen in patients who received IMRT is the
result of increased dose, the presence of hormonal therapy, the combination of
both, or other reasons.
The novel definitions of biochemical disease free survival used in this
paper do not alter the significance of the result. Our definition of post-RP failure
is more stringent than most others used in past retrospective studies,11, 19-25, 51
and the definition of post-IMRT failure used in this study has a higher sensitivity
for failure than that used in other retrospective studies, with the exception of the
review published by Keyser et al.19, 51 Therefore, it is extremely unlikely that the
novel definitions of failure utilized in this study could account for the improved
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outcome seen in IMRT patients with an intermediate or poor prognosis relative to
their RP counterparts.
Strengths of our study include a blind reabstraction to ensure reliability of
data collection and the utilization of recommended definitions of biochemical
failure. Additionally, the data was analyzed with the ASTRO and AUA
recommended definitions of failure using standard prognostic group schemes.
Limitations of our study include the restrictions of a retrospective analysis.
Although we tried to account for all possible confounding factors, it is possible
that we did not account for a patient characteristic that contributes to outcome.
Despite the fact that we have a reasonable sample size, analysis of individual
subgroups of patients, although preplanned, was conducted on a smaller group
of patients. As a result, certain known adverse prognostic factors did not achieve
statistical significance when assessing their impact on biochemical disease free
survival.
In addition, had the median follow up of our study been longer, we may
have been able to use a more robust outcome measure in place of BDFS, such
as overall survival, disease-specific survival, or metastasis free survival. Also, we
can not conclusively say that five-year BDFS rates in each cohort would correlate
with ten-year BDFS rates, the latter of which would also represent a more
meaningful outcome measure.
The variable definitions of failure that we utilized for RP and IMRT
patients represent an unavoidable limitation of the study. Although we used
definitions of failure recommended by the American Urological Association and

35
the American Society for Therapeutic Radiology and Oncology in their respective
consensus statements,54, 55 we recognize that the implications of these definitions
of failure are in fact different. We feel that there is no single definition of
biochemical failure that is appropriate for patients receiving a radical
prostatectomy and patients receiving external beam radiation therapy, because
after successful radical prostatectomy, no prostate tissue remains in the body
and therefore the PSA should be undetectable (or nearly undetectable, as
indicated by the 0.2 ng/mL threshold set by the American Urological
Association).55 After external beam radiation therapy, however, viable prostate
tissue may remain, and therefore such a definition of failure would be
inappropriate. After vigorous deliberation, the American Society for Therapeutic
Radiology and Oncology decided that the appropriate definition of failure in such
cases should be “PSA nadir + 2 ng/mL”.54 In addition, the American Urological
Association recognizes that patients treated by external beam radiation therapy
will be evaluated with a different definition of failure: “The Panel recommends the
use of the American Society for Therapeutic Radiology and Oncology criteria for
patients treated with radiation therapy”.55 In addition, six of the eight retrospective
studies cited in this manuscript comparing radical prostatectomy to external
beam radiation therapy have used varying definitions of biochemical failure.
Although a single definition of failure would have been optimal, variable posttreatment prostate physiology precluded us from using such a definition in our
study.
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Another limitation of our study pertains to the fact that 37% of patients in
the favorable prognosis group of the IMRT cohort received hormonal therapy, as
hormonal therapy is generally not indicated for this group of patients. Because
we chose biochemical disease free survival as the endpoint of the study, and
because hormonal therapy significantly reduces PSA levels, the results of our
trial could be biased in favor of the IMRT cohort, particularly the value obtained
by the log-rank test comparing Kaplan Meier curves.
Additionally, it is possible that the improved outcome seen in the IMRT
subset of the NCCN intermediate prognosis group and both the MSK and NCCN
poor prognosis groups (relative to the RP subset) is secondary to the transient
PSA-lowering effect of hormone therapy. As already discussed, this could
certainly affect the p value obtained from the log-rank test comparing survival
curves. However, five-year BDFS rates were significantly higher in IMRT patients
when compared to RP patients, and any testosterone-lowering effects caused by
hormonal therapy will have long dissipated by five years post-therapy (or 3-4
years after the conclusion of hormonal therapy). Therefore, the significant
difference in five-year BDFS rates between the RP and IMRT cohorts likely
reflects the established long-term benefit of hormonal therapy on intermediate
and poor prognosis group patients treated with external beam radiation therapy,
rather than a statistical artifact.
Zelefsky et al. have reported improved biochemical disease free survival
and distant metastases free survival rates with dose escalation beyond 75.6 Gy
in patients with an intermediate and poor prognosis,73 indicating that further dose
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escalation may be of benefit to such patients. We are now using image-guided
IMRT to dose escalate above 80 Gy, particularly in patients with an intermediate
or poor prognosis.
In conclusion, biochemical disease free survival rates in patients with
prostate adenocarcinoma appear to be related to intrinsic tumor characteristics
such as clinical stage, Gleason score, and pretreatment PSA. In addition, for
patients with a poor prognosis, and some patients with an intermediate
prognosis, IMRT to a dose greater than 72 Gy administered with hormonal
therapy may yield improved BDFS when compared to radical prostatectomy.

38
References
1.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007.

CA Cancer J Clin 2007;57:43-66.
2.

Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined

prostate cancer is increased through prostate-specific antigen-based screening. JAMA
1993;270:948-54.
3.

Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men

with clinically localized prostate cancer: a case-control, propensity modeling study
stratified by race, age, treatment and comorbidities. J Urol 2004;171:1513-9.
4.

Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing

face of low-risk prostate cancer: trends in clinical presentation and primary management.
J Clin Oncol 2004;22:2141-9.
5.

AJCC Cancer Staging Manual (6th Edition). New York, NY: Springer; 2002.

6.

Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus

watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
7.

Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing

radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med
2002;347:781-9.
8.

Ercole B, Marietti SR, Fine J, Albertsen PC. Outcomes following active

surveillance of men with localized prostate cancer diagnosed in the prostate specific
antigen era. J Urol 2008;180:1336-9; discussion 40-1.

39
9.

Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial:

a randomized trial comparing radical prostatectomy versus expectant management for the
treatment of clinically localized prostate cancer. J Urol 1994;152:1910-4.
10.

Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy

for early prostate cancer. Lancet Oncol 2003;4:233-41.
11.

D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after

radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for
clinically localized prostate cancer. JAMA 1998;280:969-74.
12.

Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for

prostate cancer: comparison with external beam radiotherapy. Radiother Oncol
2000;57:263-7.
13.

Crook J, Lukka H, Klotz L, Bestic N, Johnston M. Systematic overview of the

evidence for brachytherapy in clinically localized prostate cancer. CMAJ 2001;164:97581.
14.

Ennis RD, Peschel RE. Radiation therapy for prostate cancer. Long-term results

and implications for future advances. Cancer 1993;72:2644-50.
15.

Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus

radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502-4.
16.

Hanks GE. More on the Uro-Oncology Research Group report of radical surgery

vs. radiotherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys
1988;14:1053-4.
17.

Repetto L, Granetto C, Hall RR. Prostate cancer. Crit Rev Oncol Hematol

1998;27:145-6.

40
18.

Byhardt RW, Greenlaw RH, Jensen R, et al. Re: Radical surgery versus

radiotherapy for adenocarcinoma of the prostate. J Urol 1983;130:1205-6.
19.

Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA. Stage T1-2 prostate

cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation
therapy or surgery? Int J Radiat Oncol Biol Phys 1997;38:723-9.
20.

D'Amico AV, Whittington R, Kaplan I, et al. Equivalent biochemical failure-free

survival after external beam radiation therapy or radical prostatectomy in patients with a
pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys
1997;37:1053-8.
21.

Martinez AA, Gonzalez JA, Chung AK, et al. A comparison of external beam

radiation therapy versus radical prostatectomy for patients with low risk prostate
carcinoma diagnosed, staged, and treated at a single institution. Cancer 2000;88:425-32.
22.

Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the

efficacy of local therapies for localized prostate cancer in the prostate-specific antigen
era: a large single-institution experience with radical prostatectomy and external-beam
radiotherapy. J Clin Oncol 2002;20:3376-85.
23.

Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam

radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed
implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate
cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.
24.

Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate

cancer: radical prostatectomy, external beam radiotherapy, or permanent seed
implantation. Radiother Oncol 2004;71:29-33.

41
25.

D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after

radical prostatectomy or external beam radiation therapy for patients with clinically
localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281-6.
26.

Hatano K, Araki H, Sakai M, et al. Current status of intensity-modulated radiation

therapy (IMRT). Int J Clin Oncol 2007;12:408-15.
27.

Guckenberger M, Flentje M. Intensity-modulated radiotherapy (IMRT) of

localized prostate cancer: a review and future perspectives. Strahlenther Onkol
2007;183:57-62.
28.

Sanghani M, Mignano J. Intensity modulated radiation therapy: a review of

current practice and future directions. Technol Cancer Res Treat 2006;5:447-50.
29.

Lee AK, Frank SJ. Update on radiation therapy in prostate cancer. Hematol Oncol

Clin North Am 2006;20:857-78.
30.

Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for

localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol
Phys 2008;71:330-7.
31.

Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose

conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised
controlled trial. Lancet Oncol 2007;8:475-87.
32.

Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy

for localized prostate cancer: results of the Dutch multicenter randomized phase III trial
comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6.

42
33.

Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-

dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J
Radiat Oncol Biol Phys 1998;41:491-500.
34.

Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated radiation therapy:

supportive data for prostate cancer. Semin Radiat Oncol 2008;18:48-57.
35.

Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity

modulated conformal radiotherapy improves the outcome of localized prostate cancer. J
Urol 2001;166:876-81.
36.

Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term

outcome of high dose intensity modulated radiation therapy for patients with clinically
localized prostate cancer. J Urol 2006;176:1415-9.
37.

Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK, Hanks GE. Late

morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field
coplanar beam arrangement. Int J Radiat Oncol Biol Phys 2003;55:71-7.
38.

Smit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath JJ, van der

Werf-Messing BH. Late radiation damage in prostate cancer patients treated by high dose
external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990;18:239.
39.

Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized

radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J
Clin Oncol 2000;18:3904-11.

43
40.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen

suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
JAMA 2008;299:289-95.
41.

D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW.

6-month androgen suppression plus radiation therapy vs radiation therapy alone for
patients with clinically localized prostate cancer: a randomized controlled trial. JAMA
2004;292:821-7.
42.

Nanda A, D'Amico AV. Combined radiation and hormonal therapy or dose

escalation for men with unfavourable-risk prostate cancer: an evidence-based approach
using a synthesis of randomized clinical trials. BJU Int 2008;102:1366-8.
43.

Beekman KW, Hussain M. Hormonal approaches in prostate cancer: application

in the contemporary prostate cancer patient. Urol Oncol 2008;26:415-9.
44.

Akaza H. Current status and prospects of androgen depletion therapy for prostate

cancer. Best Pract Res Clin Endocrinol Metab 2008;22:293-302.
45.

Roach M, 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen

deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer:
long-term results of RTOG 8610. J Clin Oncol 2008;26:585-91.
46.

Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen

suppression and external irradiation in patients with locally advanced prostate cancer (an
EORTC study): a phase III randomised trial. Lancet 2002;360:103-6.
47.

Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally

advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med
1997;337:295-300.

44
48.

Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to

definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 8531. Int J Radiat Oncol Biol Phys 2005;61:1285-90.
49.

Lee I, Sandler H. Hormone therapy and radiotherapy for intermediate risk prostate

cancer. Semin Radiat Oncol 2008;18:7-14.
50.

Rosenzweig KE, Morgan WR, Lytton B, Peschel RE. Prostate specific antigen

following radiotherapy for local prostate cancer. J Urol 1995;153:1561-4.
51.

Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure

definitions based on clinical outcome in 4839 prostate cancer patients treated by external
beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003;57:92943.
52.

Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure

definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys
2006;65:1487-93.
53.

Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different

definitions of biochemical failure after external beam radiotherapy changes conclusions
about relative treatment efficacy for localized prostate cancer. Urology 2006;68:593-8.
54.

Roach M, 3rd, Hanks G, Thames H, Jr., et al. Defining biochemical failure

following radiotherapy with or without hormonal therapy in men with clinically localized
prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
Int J Radiat Oncol Biol Phys 2006;65:965-74.
55.

Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical

recurrence in patients treated for localized prostate cancer: the American Urological

45
Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and
recommendations for a standard in the reporting of surgical outcomes. J Urol
2007;177:540-5.
56.

Karakiewicz PI, Hutterer GC. Predicting outcomes in patients with urologic

cancers. Curr Opin Support Palliat Care 2007;1:153-68.
57.

Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North

Am 2003;30:219-26.
58.

Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a

multivariate analysis of factors affecting biochemical and clinical failures after radical
prostatectomy. Int J Radiat Oncol Biol Phys 1997;37:1043-52.
59.

Joniau S, Van Poppel H. Localized prostate cancer: can we better define who is at

risk of unfavourable outcome? BJU Int 2008;101 Suppl 2:5-10.
60.

Shariat SF, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms

with other methods for predicting outcomes in prostate cancer: a critical analysis of the
literature. Clin Cancer Res 2008;14:4400-7.
61.

Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of

stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol
Biol Phys 2003;57:915-28.
62.

Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE. Five-year

biochemical outcome and toxicity with transperineal CT-planned permanent I-125
prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol
Phys 2000;47:1261-6.

46
63.

Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and

morbidity of three-dimensional conformal radiotherapy versus transperineal permanent
iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999;17:517-22.
64.

National Comprehensive Cancer Network. http://nccn.org. Accessed August 1,

2008. (Accessed at
65.

Ganswindt U, Paulsen F, Corvin S, et al. Optimized coverage of high-risk

adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensitymodulated radiation therapy technique. Int J Radiat Oncol Biol Phys 2007;67:347-55.
66.

Wang D, Lawton C. Pelvic lymph node irradiation for prostate cancer: who, why,

and when? Semin Radiat Oncol 2008;18:35-40.
67.

Wilson LD, Ennis R, Percarpio B, Peschel RE. Location of the prostatic apex and

its relationship to the ischial tuberosities. Int J Radiat Oncol Biol Phys 1994;29:1133-8.
68.

Roach M, 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node

involvement using the pre-treatment prostate specific antigen and Gleason score in men
with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;28:33-7.
69.

Gilbert EH, Lowenstein SR, Koziol-McLain J, Barta DC, Steiner J. Chart reviews

in emergency medicine research: Where are the methods? Ann Emerg Med 1996;27:3058.
70.

Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a

fixed point in time. Stat Med 2007;26:4505-19.
71.

Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A

preoperative nomogram for disease recurrence following radical prostatectomy for
prostate cancer. J Natl Cancer Inst 1998;90:766-71.

47
72.

Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA.

Pretreatment nomogram for predicting the outcome of three-dimensional conformal
radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352-9.
73.

Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal

radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control
and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys
2008;71:1028-33.

